查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413826

細胞治療市場：按支架、按應用分類 - 2024-2030 年全球預測

Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞治療市場規模預估2023年為110.7億美元，2024年達124.9億美元，預計2030年將達到266.5億美元，複合年成長率為13.37%。

全球細胞治療市場

主要市場統計
基準年[2023] 110.7億美元
預測年份 [2024] 124.9億美元
預測年份 [2030] 266.5億美元
複合年成長率（%） 13.37%
細胞治療市場-IMG1

細胞療法代表再生醫學的一個分支，利用細胞成分來修復和再生組織和器官。這些成分包括多種生物分子，如蛋白質、胜肽、生長因子、細胞外基質（ECM）成分和合成的生物活性化合物，但不包括活細胞。該治療方法利用這些細胞材料的領導潛力來刺激身體的內部修復機制並為組織再生提供支架。 KEYWORD 市場成長受到慢性病盛行率增加、治療技術進步以及再生醫學研究投資增加等因素的影響。此外，政府積極支持再生醫學的努力也正在加速細胞療法的交付。然而，治療開發的高成本、嚴格的監管要求以及製造流程的複雜性影響了細胞療法的開發。細胞治療市場的潛在機會包括開拓具有增強生物相容性和生物活性的生醫材料、與科技公司合作開發先進製造技術以及開拓新興國家市場。

區域洞察

在美國，特別是美國，細胞療法已廣泛應用於多種臨床應用，包括創傷治療、整形外科治療以及最近的整容手術。 Acela 療法在美洲的生產非常複雜，嚴格的 FDA 法規確保了最高的品質和安全標準。在亞太地區，日本、韓國、中國和印度等國家正成為細胞治療的重要市場。在這些國家，不斷成長的糖尿病人口增加了這些治療方法在慢性傷口和糖尿病潰瘍治療中的使用。此外，經濟成長和醫療保健投資使亞太地區成為新興的醫療旅遊中心，直接影響細胞治療藥物等先進治療方法的使用。中國和韓國特別投資擴大產能，而日本則以其再生醫學創新而聞名。歐洲擁有成熟的細胞治療市場，擁有用於傷口護理、組織再生和外科應用的先進產品。歐洲是許多大公司的所在地，正在推動該領域的技術創新。中東和非洲部分地區也認知到了蜂窩產品的潛力，但由於廣大地區的經濟和醫療保健系統不同，其採用情況並不均衡。歐洲國家擁有符合 EMA 指南的強大生產框架，確保高品質生產。德國、英國、英國等生物技術中心擁有強大的生產能力。

FPNV定位矩陣

FPNV定位矩陣對於評估細胞治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對細胞治療市場供應商的現狀進行富有洞察力和深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-細胞治療市場的市場規模與預測是多少？

2-在細胞治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-細胞治療市場的技術趨勢和法律規範是什麼？

4-細胞治療市場主要廠商的市場佔有率是多少？

5-進入細胞治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和老齡化相關疾病的盛行率增加
      • 政府推動再生醫學和幹細胞研究的舉措
      • 提高無細胞和智慧生物材料的可用性
    • 抑制因素
      • 缺乏熟練的研究人員和有限的報銷選擇
    • 機會
      • 全球細胞治療與研發的進展
      • 醫院和醫療機構承擔的細胞治療計劃數量不斷增加。
    • 任務
      • 有關再生醫學和無細胞療法的複雜法規
  • 市場區隔分析
    • 支架：優先考慮細胞外基質以支持細胞治療
    • 應用：開發針對腫瘤部位的細胞療法
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 立足細胞治療市場

  • 含有細胞的水凝膠
  • 細胞外基質（ECM）
  • 熔融沉積建模(FDM)

第7章細胞治療市場：依應用分類

  • 心臟病學
  • 消化內科
  • 肝病學
  • 神經病學
  • 腫瘤學

第8章美洲細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析
    • 新產品發布和功能增強

第12章競爭產品組合

  • 主要公司簡介
    • Allergan Inc. by Abbvie Inc.
    • AlloSource
    • Aziyo Biologics
    • Baxter International
    • Becton, Dickinson and Company
    • BioHorizons, Inc.
    • EnColl Corporation
    • Engitix Ltd
    • Fidia Farmaceutici SpA
    • GSK PLC
    • Humacyte, Inc.
    • In2Bones Global by CONMED Corporation
    • Integra LifeSciences Corporation
    • LifeNet Health
    • MiMedx Group
    • Organicell Regenerative Medicine, Inc.
    • Organogenesis Holdings Inc.
    • Reprise Biomedical, Inc.
    • Sanofi SA
    • Smith & Nephew PLC
    • Stryker Corporation
    • Tissue Regenix
    • Vascudyne, Inc.
    • Zimmer Biomet
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-5A3042B3D695

[196 Pages Report] The Acellular Therapy Market size was estimated at USD 11.07 billion in 2023 and expected to reach USD 12.49 billion in 2024, at a CAGR 13.37% to reach USD 26.65 billion by 2030.

Global Acellular Therapy Market

KEY MARKET STATISTICS
Base Year [2023] USD 11.07 billion
Estimated Year [2024] USD 12.49 billion
Forecast Year [2030] USD 26.65 billion
CAGR (%) 13.37%
Acellular Therapy Market - IMG1

Acellular therapy represents a branch of regenerative medicine that utilizes acellular components with the goal of repairing or regenerating tissues and organs. These components can include various biomolecules such as proteins, peptides, growth factors, extracellular matrix (ECM) components, and synthetic bioactive compounds but lack any living cells. This form of therapy harnesses the instructive potential of these acellular materials to stimulate the body's intrinsic repair mechanisms or to provide a scaffold for tissue regeneration. The growth of the acellular therapy market is influenced by factors such as the increasing prevalence of chronic diseases, advancements in treatment technology, and growing investments in regenerative medicine research. Further, favorable government initiatives to support regenerative medicine have also accelerated the provision of acellular therapy. However, the high cost of therapy development, stringent regulatory requirements, and the complexity of the manufacturing process impact the acellular therapy development. Potential opportunities within the acellular therapy market include the development of biomaterials with enhanced biocompatibility and bioactivity, collaboration with technology companies for advanced manufacturing techniques, and exploring untapped markets in developing countries.

Regional Insights

The Americas, particularly the United States, have witnessed widespread adoption of acellular therapy across multiple clinical applications, including wound healing, orthopedic treatments, and, increasingly, cosmetic procedures. The production of acellular therapies in the Americas is highly sophisticated, with stringent FDA regulations ensuring the highest quality and safety standards. In the APAC region, countries such as Japan, South Korea, China, and India are emerging as significant markets for acellular therapy. These countries are seeing increasing use of these therapies in managing chronic wounds and diabetic ulcers due to a growing diabetic population. Further, growing economies and healthcare investments have seen the APAC become a burgeoning medical tourism hub, directly impacting the use of advanced therapies such as acellular therapeutics. China and South Korea are particularly invested in scaling up production capacity, and Japan is known for its innovation in regenerative medicine. Europe has a well-established acellular therapy market, with advanced products used in wound care, tissue regeneration, and surgical applications. The presence of a number of leading companies here drives innovation in the sector. The Middle East and parts of Africa are also recognizing the potential for acellular products; however, their adoption is varied due to differing economic and healthcare systems within the vast region. European countries have robust production frameworks governed by EMA guidelines, which ensure high-quality production. Biotechnology hubs in countries including Germany, the UK, and France have strong production capabilities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acellular Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acellular Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Scaffold
    • Cell Laden Hydrogel
    • Extracellular Matrix (ECM)
    • Fused Deposition Modeling (FDM)
  • Application
    • Cardiology
    • Gastroenterology
    • Hepatology
    • Neurology
    • Oncology
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acellular Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acellular Therapy Market?

3. What are the technology trends and regulatory frameworks in the Acellular Therapy Market?

4. What is the market share of the leading vendors in the Acellular Therapy Market?

5. Which modes and strategic moves are suitable for entering the Acellular Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Acellular Therapy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
      • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
      • 5.1.1.3. Increased availability of acellular and smart biomaterials
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
      • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
    • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Acellular Therapy Market, by Scaffold

  • 6.1. Introduction
  • 6.2. Cell Laden Hydrogel
  • 6.3. Extracellular Matrix (ECM)
  • 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiology
  • 7.3. Gastroenterology
  • 7.4. Hepatology
  • 7.5. Neurology
  • 7.6. Oncology

8. Americas Acellular Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Acellular Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player
    • 11.3.1. New Product Launch & Enhancement
      • 11.3.1.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
      • 11.3.1.2. MTF Biologics to Launch New Acellular Human Reticular Dermal Allograft
      • 11.3.1.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Allergan Inc. by Abbvie Inc.
    • 12.1.2. AlloSource
    • 12.1.3. Aziyo Biologics
    • 12.1.4. Baxter International
    • 12.1.5. Becton, Dickinson and Company
    • 12.1.6. BioHorizons, Inc.
    • 12.1.7. EnColl Corporation
    • 12.1.8. Engitix Ltd
    • 12.1.9. Fidia Farmaceutici S.p.A
    • 12.1.10. GSK PLC
    • 12.1.11. Humacyte, Inc.
    • 12.1.12. In2Bones Global by CONMED Corporation
    • 12.1.13. Integra LifeSciences Corporation
    • 12.1.14. LifeNet Health
    • 12.1.15. MiMedx Group
    • 12.1.16. Organicell Regenerative Medicine, Inc.
    • 12.1.17. Organogenesis Holdings Inc.
    • 12.1.18. Reprise Biomedical, Inc.
    • 12.1.19. Sanofi S.A.
    • 12.1.20. Smith & Nephew PLC
    • 12.1.21. Stryker Corporation
    • 12.1.22. Tissue Regenix
    • 12.1.23. Vascudyne, Inc.
    • 12.1.24. Zimmer Biomet
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACELLULAR THERAPY MARKET DYNAMICS
  • FIGURE 7. ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
  • FIGURE 8. ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 6. ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 10. ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 102. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ACELLULAR THERAPY MARKET LICENSE & PRICING